Research paper
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
Study answer
What this study found
High-dose oral iron did not improve exercise capacity or related clinical outcomes over 16 weeks. The primary endpoint, change in peak VO2, was +23 mL/min with oral iron versus -2 mL/min with placebo, for a between-group difference of 21 mL/min (95% CI, -34 to +76; P = .46). The 6-minute walk distance changed by 15 m versus 21 m, with a difference in change of -1 m (95% CI, -24 to 23; P = .95), and NT-proBNP showed no meaningful between-group difference (159 pg/mL; P = .48). KCCQ clinical summary score also did not significantly differ (difference 3.4; P = .08), and adverse events were…
- Study & population
- Randomized clinical trial in adults with heart failure with reduced ejection fraction (LVEF 40%) and iron deficiency who were stable on guideline-directed medical therapy.
- Intervention
- Oral iron polysaccharide, 150 mg by mouth twice daily for 16 weeks, compared with placebo.
- Key limitation
- The treatment period was short at 16 weeks, which may limit detection of longer-term effects.
View source
Open PDFOriginal abstract
Importance Iron deficiency is present in approximately 50% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of i…